Benefits
Episodic memory in healthy elderly
Memophenol™ at 600 mg/day improved episodic memory versus placebo in healthy older adults. Strongest effects in those starting with lower baseline memory — supports use as supportive intervention for early age-related memory decline.
Mild cognitive impairment support
In adults with mild cognitive impairment, Memophenol™ at 300 mg/day improved processing speed, visuospatial learning, and executive function. Important honest note: the primary endpoint (episodic memory) was not statistically different in this MCI population.
Acute cognitive enhancement in young adults
In healthy young adults, a single 600 mg dose of Memophenol™ improved performance on a serial subtraction task, with a trend toward improved rapid visual processing. Demonstrates broader age applicability beyond the elderly trials.
Synergistic grape + blueberry absorption
Combining grape and blueberry polyphenols increases plasma levels of blueberry phenolic metabolites 3-5 fold compared to delivery in isolation. Complementary polyphenol profiles: grape provides resveratrol and proanthocyanidins; blueberry provides cyanidin glycosides and procyanidins.
BDNF and neurotrophic effects (preclinical)
Animal studies show Memophenol™ administration improves spatial navigation in middle-aged mice, modulates neuroplasticity, increases nerve growth factor mRNA expression, and increases new neuron generation. Mechanistic preclinical evidence supporting the cognitive trial outcomes.
Multi-domain cognitive profile
Across the two main human trials, Memophenol™ shows benefits across both episodic memory (healthy elderly) and executive function (MCI population) — an aging-relevant cognitive profile spanning the domains where intervention is most clinically needed.
Mechanism of action
Combined grape + blueberry polyphenol synergy
Grape polyphenols (resveratrol, proanthocyanidins) + blueberry polyphenols (cyanidin glycosides, pterostilbene) provide multi-target polyphenol profile. Animal data shows 3-5x increased plasma metabolite concentrations vs isolated administration — synergistic absorption mechanism. Distinguishes from single-source extracts.
BDNF and synaptic plasticity enhancement
A mouse study demonstrated increased nerve growth neurotrophic factor mRNA expression with Memophenol. Modulation of neuroplasticity, increased neurogenesis with prolongation morphology. Mechanism for age-related cognitive maintenance.
BBB penetration via diverse anthocyanin profile
Multiple anthocyanins (cyanidin, peonidin, delphinidin, malvidin glycosides) provide diverse BBB penetration profiles. Combined extract delivers more comprehensive CNS polyphenol exposure than single-source extracts.
Vascular endothelial function via NO production
Polyphenols improve endothelial NO production — better cerebral perfusion. Mechanism complementary to direct CNS effects. Both grape and blueberry components contribute.
Antioxidant via direct ROS scavenging
Comprehensive polyphenol antioxidant profile from combined extracts. Direct scavenging of hydroxyl, peroxyl, superoxide radicals plus enhancement of endogenous antioxidant defenses.
Anti-inflammatory pathway modulation
NF-κB, COX-2, iNOS suppression via polyphenol mechanisms. Reduced neuroinflammation contributing to cognitive decline.
Pterostilbene mechanism (blueberry component)
Blueberry contains pterostilbene — methylated resveratrol analog with superior bioavailability. SIRT1 activation, mitochondrial biogenesis, neuroprotection. Distinct mechanism complementing grape resveratrol.
Clinical trials
Bicentric double-blind randomized placebo-controlled clinical study (Bensalem J, Dudonne S, Etchamendy N, Pellay H, Amadieu C, Gaudout D et al. 2019, J Gerontol A Biol Sci Med Sci 74(7):996-1007, doi:10.1093/gerona/gly166).
215 men and women aged 60-70 years, healthy elderly. Memophenol™ 600 mg/day (258 mg flavonoids) vs placebo for 6 months. Computer-based cognitive testing including episodic memory and visuospatial skills.
Significant improvements in episodic memory particularly in subjects with lower memory baseline performance. Subgroup analysis identified responder population. Foundational positive clinical trial supporting Memophenol™ episodic memory claims. Industry-sponsored (Activ'Inside) — important context for evidence interpretation. Subgroup-dependent efficacy important context.
Two-arm parallel-group randomized double-blind placebo-controlled trial (Lopresti AL, Smith SJ, Drummond PD, Front Psychol 14:1144231, doi:10.3389/fpsyg.2023.1144231).
143 volunteers aged 60-80 years with mild cognitive impairment (MCI). Memophenol™ 150 mg twice daily (300 mg/day) vs placebo for 6 months. Multiple cognitive assessments.
Memophenol™ associated with greater improvements in processing speed (p=0.020), visuospatial learning (p=0.012), BRIEF-A executive function global score (p=0.046). NO statistical difference in other cognitive domains including episodic memory (the primary outcome) — important honest counter-finding. Memophenol™ well-tolerated with no significant adverse reactions. Authors: 'preliminary positive results require further investigation in robust clinical trials.' industry-sponsored (Activ'Inside provided product). Mixed results pattern.
Acute administration trial (Philip P, Sagaspe P, Taillard J, Mandon C, Constans J, Pourtau L et al. 2019).
30 healthy students aged 18-25 years. Single 600 mg Memophenol™ dose vs placebo.
Increased performance on serial three-subtraction task. Trend toward improved performance on rapid visual information processing task. Smaller acute trial in younger population complementing long-term elderly evidence. Demonstrates broader age applicability.